APA (7th ed.) Citation

T, M., Z, R., HJ, C., JO, P., JW, K., T, P., . . . AB, E. (2025). Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43(5), 545. https://doi.org/10.1200/JCO.24.00337

Chicago Style (17th ed.) Citation

T, Macarulla, et al. "Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 43, no. 5 (2025): 545. https://doi.org/10.1200/JCO.24.00337.

MLA (9th ed.) Citation

T, Macarulla, et al. "Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 43, no. 5, 2025, p. 545, https://doi.org/10.1200/JCO.24.00337.